NPPB and cardiac amyloidosis: In another study, Almo and colleagues [46] examined the safety and efficacy of levoslmendan In patients with cardiac amyloidosis (CA), finding that while levoslmendan was generally safe, It led to Improvements In urinary output and body weight without significantly affecting NT-proBNP or renal function.